Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OXTR | P30559 | 13/20 | 0.82 |
| ▸ | AVPR1A | P37288 | 6/20 | 0.82 |
| ▸ | AVPR2 | P30518 | 4/20 | 0.82 |
| ▸ | AVPR1B | P47901 | 4/20 | 0.82 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.76 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.76 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16790726 | 0.93 | OXTR (0.86) | OXTRAVPR1AAVPR2AVPR1B | |
| SCHEMBL15511602 | 0.92 | OXTR (0.81) | OXTRAVPR1AAVPR2AVPR1B | |
| Oxytocin SCHEMBL29048 | 0.90 | OXTR (1.00) | OXTRAVPR1AAVPR2AVPR1B | |
| Oxytocin SCHEMBL8370159 | 0.90 | OXTR (1.00) | OXTRAVPR1AAVPR2AVPR1B | |
| Oxytocin SCHEMBL14085374 | 0.90 | OXTR (1.00) | OXTRAVPR1AAVPR2AVPR1B | |
| Oxytocin SCHEMBL16373316 | 0.90 | OXTR (1.00) | OXTRAVPR1AAVPR2AVPR1B | |
| Oxytocin SCHEMBL1173243 | 0.90 | OXTR (1.00) | OXTRAVPR1AAVPR2AVPR1B | |
| Oxytocin SCHEMBL20707334 | 0.90 | OXTR (1.00) | OXTRAVPR1AAVPR2AVPR1B | |
| Oxytocin SCHEMBL21527573 | 0.90 | OXTR (1.00) | OXTRAVPR1AAVPR2AVPR1B | |
| SCHEMBL15511771 | 0.90 | OXTR (0.77) | OXTRAVPR1AAVPR2AVPR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4121531-A1 | COMPOSITIONS AND METHODS COMPRISING IMPROVED GUIDE RNAS | Cornell University (US) | 2023-01-25 | — | — | EP | claimed |
| US-20260034142-A1 | Therapeutic Compounds and Compositions for Treating Social Disorders and Substance Use Disorders | Kinoxis Therapeutics Pty Ltd (AU) | 2026-02-05 | — | — | US | disclosed |
| US-12458648-B2 | Therapeutic compounds and compositions for treating social disorders and substance use disorders | KINOXIS THERAPEUTICS PTY LTD. (AU) | 2025-11-04 | — | — | US | disclosed |
| US-20250197820-A1 | NUCLEIC ACID POLYMERASE AND ITS USE IN PRODUCING NON-DNA NUCLEOTIDE POLYMERS | UNITED KINGDOM RESEARCH AND INNOVATION (GB) | 2025-06-19 | — | — | US | disclosed |
| US-20240425846-A1 | METHODS OF BIOMOLECULE DISPLAY | RES & INNOVATION UK (GB) | 2024-12-26 | — | — | US | disclosed |
| US-20240409995-A1 | SINGLE-MOLECULE PEPTIDE SEQUENCING THROUGH MOLECULAR BARCODING AND EX-SITU ANALYSIS | GLYPHIC BIOTECHNOLOGIES, INC. | 2024-12-12 | — | — | US | disclosed |
| EP-4449128-A2 | SINGLE-MOLECULE PEPTIDE SEQUENCING THROUGH MOLECULAR BARCODING AND EX-SITU ANALYSIS | Glyphic Biotechnologies, Inc. (US) | 2024-10-23 | — | — | EP | disclosed |
| CN-118679389-A | Single molecule peptide sequencing by molecular barcoding and ex situ analysis | 格里菲克生物技术公司 | 2024-09-20 | — | — | CN | disclosed |
| US-20240245706-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS FOR TREATING SOCIAL DISORDERS AND SUBSTANCE USE DISORDERS | Kinoxis Therapeutics Pty Ltd (AU) | 2024-07-25 | — | — | US | disclosed |
| EP-4399328-A1 | METHODS OF BIOMOLECULE DISPLAY | United Kingdom Research and Innovation (GB) | 2024-07-17 | — | — | EP | disclosed |
| EP-4317418-A1 | METHOD FOR PRODUCING OVARIAN SOMATIC CELL-LIKE CELLS, AND METHOD FOR INDUCING DIFFERENTIATION OF PRIMATE PLURIPOTENT STEM CELLS INTO OVARIAN SOMATIC CELL-LIKE CELLS | Kyoto University (JP) | 2024-02-07 | — | — | EP | disclosed |
| US-11890287-B2 | Therapeutic compounds and compositions for treating social disorders and substance use disorders | Kinoxis Therapeutics Pty Ltd (AU) | 2024-02-06 | — | — | US | disclosed |
| WO-2023114732-A2 | SINGLE-MOLECULE PEPTIDE SEQUENCING THROUGH MOLECULAR BARCODING AND EX-SITU ANALYSIS | GLYPHIC BIOTECHNOLOGIES, INC. (US) | 2023-06-22 | — | — | WO | disclosed |
| WO-2023036772-A1 | METHODS OF BIOMOLECULE DISPLAY | UNITED KINGDOM RESEARCH AND INNOVATION (GB) | 2023-03-16 | — | — | WO | disclosed |
| WO-2023036779-A2 | NUCLEIC ACID POLYMERASES | UNITED KINGDOM RESEARCH AND INNOVATION (GB) | 2023-03-16 | — | — | WO | disclosed |
| US-20220362261-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS FOR TREATING SOCIAL DISORDERS AND SUBSTANCE USE DISORDERS | THE UNIVERSITY OF SYDNEY (AU) | 2022-11-17 | — | — | US | disclosed |
| WO-2022211054-A1 | METHOD FOR PRODUCING OVARIAN SOMATIC CELL-LIKE CELLS, AND METHOD FOR INDUCING DIFFERENTIATION OF PRIMATE PLURIPOTENT STEM CELLS INTO OVARIAN SOMATIC CELL-LIKE CELLS | 国立大学法人京都大学 | 2022-10-06 | — | — | WO | disclosed |
| EP-3328864-B1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS FOR TREATING SOCIAL DISORDERS AND SUBSTANCE USE DISORDERS | Kinoxis Therapeutics Pty Ltd (AU) | 2022-09-07 | — | — | EP | disclosed |
| EP-3640328-B1 | ENZYMES | RES & INNOVATION UK (GB) | 2022-08-17 | — | — | EP | disclosed |
| US-20140066373-A1 | TREATING DIABETES WITH OXYTOCIN OR OXYTOCIN ANALOGS | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2014-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240245706-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS FOR TREATING SOCIAL DISORDERS AND SUBSTANCE USE DISORDERS | SLC18A2, SLC6A3, CES2 | OXTR 148/4885AVPR1A 555/4885AVPR2 691/4885 |
| US-12458648-B2 | Therapeutic compounds and compositions for treating social disorders and substance use disorders | SLC18A2, SLC6A3, CES2 | OXTR 148/4885AVPR1A 555/4885AVPR2 691/4885 |
| US-11890287-B2 | Therapeutic compounds and compositions for treating social disorders and substance use disorders | SLC18A2, SLC6A3, CES2 | OXTR 148/4885AVPR1A 555/4885AVPR2 691/4885 |
| US-20260034142-A1 | Therapeutic Compounds and Compositions for Treating Social Disorders and Substance Use Disorders | SLC6A3, SLC6A4, SLC6A1 | OXTR 6/4885AVPR1A 412/4885AVPR2 375/4885 |
| US-20220362261-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS FOR TREATING SOCIAL DISORDERS AND SUBSTANCE USE DISORDERS | SLC18A2, SLC6A3, CES2 | OXTR 148/4885AVPR1A 555/4885AVPR2 691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.